Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
494.20    -5.20 (-1.04%)
Bid:
494.00
Ask:
494.80
Spread: 0.80 (0.162%)
Market Cap: £1.34b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

POST-CLOSE STATEMENT

14 Nov 2017 07:00

RNS Number : 3823W
Chemring Group PLC
14 November 2017
 

FOR IMMEDIATE RELEASE 14 NOVEMBER 2017

 

CHEMRING GROUP PLC

 

POST-CLOSE STATEMENT

 

Chemring Group PLC ("Chemring" or "the Group") today provides its post-close statement in respect of the year ended 31 October 2017.

 

FY17 trading

 

The Group's trading performance for the year to 31 October 2017 ("FY17") is expected to be slightly ahead of the Board's expectations.

 

Strong delivery performance in the final quarter of FY17 has led to full year revenue of £547m, an increase of 15% on the prior year (2016: £477m).

 

The Group's order book at 31 October 2017 was £478m (2016: £593m). The decline in the order book principally reflects the conclusion of the 40mm ammunition contract to a customer in the Middle East, awarded in 2016, as well as a currency headwind of £33m experienced this year. A number of significant orders were received by both our US and UK Countermeasures businesses in the second half of the year, giving increased confidence in the Group's prospects in the near term.

 

Financial position

 

At 31 October 2017, net debt was £80.0m (2016: £87.6m).

 

Of the Group's £114.3m outstanding US private placement loan notes, £51.3m was repaid yesterday, 13 November 2017, from existing bank debt facilities and cash resources. The remaining loan notes are scheduled to be repaid in November 2019 (£63.0m).

 

The Group's FY17 results are scheduled to be announced on 18 January 2018.

 

-ENDS-

 

For further information:

 

Rupert Pittman Group Director of Corporate Affairs, 01794 833901

Chemring Group PLC

 

Andrew Jaques MHP Communications 020 3128 8100

James White

 

Notes to editors

· Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,500 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under three strategic product segments: Countermeasures, Sensors, and Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.co.uk

 

Cautionary statements

This announcement contains unaudited information based on management accounts and forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

 

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

 

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

No statement in this announcement is intended as a profit forecast for FY17 and no statement in this announcement should be interpreted to mean that underlying operating profit for the current or future financial years would necessarily be above a minimum level, or match or exceed the historical published underlying operating profit or set a minimum level of underlying operating profit.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGGGBUGUPMPPW
Date   Source Headline
2nd Oct 202012:31 pmRNSHolding(s) in Company
2nd Oct 202010:36 amRNSDirector/PDMR Shareholding
1st Oct 20205:48 pmRNSTotal Voting Rights
30th Sep 20207:00 amRNSContract Awards
24th Sep 20204:08 pmRNSHolding(s) in Company
16th Sep 202012:02 pmRNSPrice Monitoring Extension
15th Sep 202012:02 pmRNSPrice Monitoring Extension
15th Sep 202011:03 amRNSHolding(s) in Company
15th Sep 20207:00 amRNSTrading Update
11th Sep 202011:49 amRNSHolding(s) in Company
1st Sep 202011:34 amRNSTotal Voting Rights
27th Aug 202012:08 pmRNSSecond Price Monitoring Extn
27th Aug 202012:02 pmRNSPrice Monitoring Extension
26th Aug 202012:02 pmRNSPrice Monitoring Extension
21st Aug 20202:44 pmRNSHolding(s) in Company
17th Aug 202012:02 pmRNSPrice Monitoring Extension
12th Aug 202011:30 amRNSHolding(s) in Company
3rd Aug 20209:54 amRNSTotal Voting Rights
31st Jul 202012:07 pmRNSSecond Price Monitoring Extn
31st Jul 202012:02 pmRNSPrice Monitoring Extension
30th Jul 202011:22 amRNSDirector/PDMR Shareholding
30th Jul 202011:18 amRNSDirector/PDMR Shareholding
14th Jul 202012:07 pmRNSSecond Price Monitoring Extn
14th Jul 202012:02 pmRNSPrice Monitoring Extension
10th Jul 202012:07 pmRNSSecond Price Monitoring Extn
10th Jul 202012:02 pmRNSPrice Monitoring Extension
8th Jul 202012:07 pmRNSSecond Price Monitoring Extn
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 20204:02 pmRNSHolding(s) in Company
6th Jul 20202:03 pmRNSHolding(s) in Company
6th Jul 20201:58 pmRNSHolding(s) in Company
2nd Jul 202012:02 pmRNSPrice Monitoring Extension
1st Jul 202011:36 amRNSTotal Voting Rights
22nd Jun 20204:26 pmRNSDirector/PDMR Shareholding
19th Jun 20209:34 amRNSBlock listing update
19th Jun 20209:28 amRNSBlock listing Interim Review
3rd Jun 20207:00 amRNSDirectorate Change
3rd Jun 20207:00 amRNSInterim Results
1st Jun 20209:20 amRNSTotal Voting Rights
27th May 202011:16 amRNSHolding(s) in Company
7th May 20207:00 amRNSCompletion of disposal
1st May 202011:39 amRNSTotal Voting Rights
29th Apr 202010:31 amRNSDisclosure of Rights Attached to Equity Shares
20th Apr 20207:05 amRNSDirector Declaration
14th Apr 20207:00 amRNSCovid-19 Update
7th Apr 202012:07 pmRNSSecond Price Monitoring Extn
7th Apr 202012:02 pmRNSPrice Monitoring Extension
3rd Apr 202012:34 pmRNSTotal Voting Rights
1st Apr 20201:36 pmRNSTotal Voting Rights
30th Mar 20204:09 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.